Table 1.

History of regulatory events

Date	FDA decisions
26 February 2004	FDA approval of bevacizumab as first-line treatment for metastatic colorectal cancer in combination with intravenous 5-fluorouracil
20 June 2006	FDA approval of bevacizumab as second-line treatment for metastatic colorectal cancer
5 December 2007	ODAC voted 5 to 4 against the recommendation bevacizumab for treatment of metastatic breast cancer in combination with paclitaxel
22 February 2008	FDA granted accelerated approval of bevacizumab in combination with paclitaxel for the treatment of metastatic breast cancer
20 July 2010	ODAC voted 12 to 1 revoking approval of bevacizumab for the treatment of metastatic HER2 negative breast cancer
16 December 2010	FDA initiated the withdrawal process
16 January 2011	Genentech requested an hearing
28–29 June 2011	FDA Oncologic Drugs Advisory Committee hearing recommended the indication withdrawal
18 November 2011	FDA withdrew officially the indication